Italian study to track CAR-T success in leukemia patients

NCT ID NCT07623655

Not yet recruiting Knowledge-focused Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow 107 children and adults with B-cell acute lymphoblastic leukemia who are treated with approved CAR-T cell therapies in Italy. Researchers will collect data from medical records to see how many patients achieve a response. The goal is to understand how well these treatments work in everyday medical practice.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CAR-T cells (tisagenlecleucel, brexucabtagene autoleucel, obecabtagene autoleucel)
What this could lead to: If successful, this study could confirm how well approved CAR-T therapies work in real-world settings for B-cell acute lymphoblastic leukemia.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It only looks at patients already prescribed these therapies, which may limit generalizability.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Burkitt lymphoma precursor B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA

More trials for these conditions

Other studies related to the condition(s) this trial covers.